#USA #Washington, D.C. #medical cannabis #Patient First Coalition #Schedule III

Introduction

On June 1, 2026, the Patient First Coalition (PFC), representing over 1,100 Ambassadors from more than 50 advocacy organizations, expressed strong support for the Drug Enforcement Administration's (DEA) ongoing review and public hearing regarding the potential reclassification of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. This proposed transition is significant as it embodies a move toward a more accessible and responsible approach to medical cannabis that prioritizes patient welfare.

Understanding the Coalition's Role

The Patient First Coalition’s Medical Cannabis Committee is composed of 85 diverse stakeholders that include healthcare professionals, patient advocates, insurance experts, pharmacists, technology innovators, and cannabis industry representatives. For the past year, this multi-disciplinary group has been engaged in formulating a comprehensive set of recommendations aimed at creating a patient-centered strategy for this pivotal transition.

A Call for a Moratorium

As the DEA prepares for its public hearing, scheduled for June 29, 2026, the Committee is advocating for a temporary moratorium to allow for adequate preparation and public insight into the complexities of transitioning medical cannabis. They believe that this period will be beneficial for both the administration and the healthcare community to develop a thorough understanding of the implications of the change.

Comprehensive Blueprint for Transition

The coalition has dedicated substantial effort to drafting recommendations, organized through seven specialized sub-committees. These include focused discussions on:
1. Patient Access: Ensuring that patients easily receive the medical cannabis they need.
2. Whole Plant Protections: Advocating for the integrity of cannabis products that patients require.
3. Physician Participation: Encouraging doctors to engage in prescribing and advising on medical cannabis.
4. Insurance Integration: Collaborating with insurance providers to include medical cannabis in coverage plans.
5. Pharmacy and Dispensary Standards: Establishing consistent guidelines for dispensaries to ensure quality patient service.
6. Technology Connectivity: Leveraging technological advancements to improve patient care and access to cannabis.
7. Research Expansion: Promoting the need for further clinical studies on the efficacy of medical cannabis treatments.

Insights from Coalition Leaders

Kari Boiter, a member of the PFC Medical Cannabis Committee remarked, 'The transition of medical cannabis is one of the most significant shifts in healthcare policy today. Our goal is to ensure this change is executed in a manner that safeguards and prioritizes patient welfare.'

Moreover, Priscilla Agoncillo, another Committee member, noted, 'As we navigate this new era for medical cannabis, we have the chance to establish an industry founded on integrity and patient safety. Thoughtful standards will build trust and bolster responsible innovations.'

A Legislative Platform for the Future

The formal presentation of the recommendations will coincide with National Medical Cannabis Day, set to take place on July 23, 2026, in Washington, D.C. The event will gather legislators, healthcare professionals, researchers, and patient advocates to engage in critical discussions regarding the future policy of medical cannabis in the United States.

Conclusion

The Patient First Coalition firmly believes that the transition of medical cannabis to a Schedule III classification represents an important moment for patients, medical professionals, and the healthcare system as a whole. As the DEA embarks on this review process, the coalition remains committed to fostering an environment where patient-focused policies take precedence, ensuring that the future of medical cannabis is both innovative and equitable. With the support of organizations like the American Council of Cannabis Medicine, they are working towards a transformative future that embraces the potential of medical cannabis in patient care.

For further inquiries or detailed information, visit Patient First Coalition.